可溶性肿瘤坏死因子受体（p75）融合蛋白（恩利）用于类风湿关节炎的治疗。
Soluble tumor necrosis factor receptor (p75) fusion protein (ENBREL) as a therapy for rheumatoid arthritis.
作者信息
Moreland L W
机构信息
Department of Medicine, University of Alabama at Birmingham, USA.
出版信息
Rheum Dis Clin North Am. 1998 Aug;24(3):579-91. doi: 10.1016/s0889-857x(05)70027-2.
Soluble tumor necrosis factor (TNF) receptor fusion protein (p75) (Enbrel) is a reversible inhibitor of the biologic effects of TNF. Enbrel has been shown in placebo-controlled trials to significantly improve the signs and symptoms of rheumatoid arthritis. Clinical trials are now in progress to assess the safety and efficacy of Enbrel in combination with methotrexate in refractory rheumatoid arthritis along with trials to compare Enbrel to methotrexate in patients with early rheumatoid arthritis.
可溶性肿瘤坏死因子（TNF）受体融合蛋白（p75）（恩利）是TNF生物学效应的可逆抑制剂。在安慰剂对照试验中已表明，恩利可显著改善类风湿性关节炎的体征和症状。目前正在进行临床试验，以评估恩利与甲氨蝶呤联合用于难治性类风湿性关节炎的安全性和有效性，同时也有试验在早期类风湿性关节炎患者中将恩利与甲氨蝶呤进行比较。
Zotero 插件